Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Recent & Breaking News (NDAQ:CPRX)

SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses From Investment in Catalyst Pharmaceutical Partners, Inc. to Contact Brower Piven Before the December 24, 2013 Lead Plaintiff Deadline -- CPRX

Globe Newswire October 29, 2013

Catalyst Pharmaceutical Updates on Its Development Activities for Firdapse(TM)

Globe Newswire October 29, 2013

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Catalyst Pharmaceutical Partners Inc.

PR Newswire October 28, 2013

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against Catalyst Pharmaceutical Partners, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 24, 2013 -- CPRX

Globe Newswire October 28, 2013

The Rosen Law Firm Files Securities Fraud Class Action Against Catalyst Pharmaceutical Partners, Inc. - CPRX

Business Wire October 25, 2013

The Rosen Law Firm Announces Investigation of Securities Claims Against Catalyst Pharmaceutical Partners, Inc.- CPRX

Business Wire October 21, 2013

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Catalyst Pharmaceutical Partners, Inc.

Business Wire October 18, 2013

Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase lll Clinical Trial for Firdapse(TM)

Globe Newswire October 15, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on CPRX, HOLX, ROVI and SPR

Accesswire September 25, 2013

Catalyst Pharmaceutical Partners to Present at Aegis Capital 2013 Healthcare Conference

Globe Newswire September 25, 2013

Catalyst Pharmaceutical Partners, Inc. Closes Previously Announced $15.1 Million Registered Direct Offering

Globe Newswire September 10, 2013

Catalyst Pharmaceutical Partners Prices Registered Direct Public Offering

Globe Newswire September 5, 2013

Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 15th Annual Global Investment Conference

Globe Newswire September 3, 2013

InvestorsGuru.com 39 Filtered Mid-Day Market Movers Recap

Investors Guru September 1, 2013

TSLA, AGNC, FB and CPRX added to NASDAQ Active Stock Watch List at EPR

Accesswire August 28, 2013

Five Star Equities Issues New Research Reports on ACUR, AKRX, CPRX and SNX

Accesswire August 28, 2013

Catalyst Pharmaceutical Partners Receives Breakthrough Therapy Designation From FDA for Firdapse(TM) for the Treatment of LEMS

Globe Newswire August 27, 2013

Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid Price Rule

Globe Newswire August 2, 2013

InvestorsGuru.com 43 Filtered Mid-Day Market Movers Recap

Stockhouse.com July 21, 2013

Catalyst Pharmaceutical Partners Provides Update on FIRDAPSE(TM) Progress

Globe Newswire June 27, 2013